# Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

> **NCT02466425** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 264 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** SHP465
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02466425
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-18
- **Primary completion:** 2016-02-16
- **Final completion:** 2016-02-16
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2021-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02466425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02466425, "Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02466425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*